Kura Oncology, Inc. (KURA): Operating Cash Flow
-$64.06M
Year ended 2025-12-31
-$111.76M
Trailing 12 months to 2026-06-30
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$64.06M | n/m | 2026-03-05, From 2025-01-01 |
| 2024-12-31 | $134.32M | n/m | 2026-03-05, From 2024-01-01 |
| 2023-12-31 | -$124.82M | n/m | 2026-03-05, From 2023-01-01 |
| 2022-12-31 | -$110.06M | n/m | 2025-02-28, From 2022-01-01 |
| 2021-12-31 | -$104.55M | n/m | 2024-02-27, From 2021-01-01 |
| 2020-12-31 | -$69.83M | n/m | 2023-02-23, From 2020-01-01 |
| 2019-12-31 | -$54.76M | n/m | 2022-02-24, From 2019-01-01 |
| 2018-12-31 | -$48.66M | n/m | 2021-02-24, From 2018-01-01 |
| 2017-12-31 | -$28.44M | n/m | 2020-02-25, From 2017-01-01 |
| 2016-12-31 | -$25.35M | n/m | 2018-03-12, From 2016-01-01 |
| 2015-12-31 | -$17.93M | n/m | 2017-03-14, From 2015-01-01 |
| 2014-12-31 | -$16.0K | n/m | 2015-02-27, From 2014-01-01 |
| 2013-12-31 | -$23.2K | n/m | 2015-02-27, From 2013-01-01 |
| 2012-12-31 | -$24.4K | n/m | 2014-03-31, From 2012-01-01 |
| 2011-12-31 | -$22.7K | n/m | 2013-03-28, From 2011-01-01 |
| 2010-12-31 | -$19.2K | n/a | 2012-03-30, From 2010-01-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| Kura Oncology, Inc. (KURA) | 2025-12-31 | -$64.06M | n/m |
| Spero Therapeutics, Inc. (SPRO) | 2025-12-31 | -$12.62M | n/m |
| Rockwell Medical, Inc. (RMTI) | 2025-12-31 | -$659.0K | n/m |
| Enanta Pharmaceuticals Inc (ENTA) | 2025-09-30 | -$19.27M | n/m |
| Viridian Therapeutics, Inc. (VRDN) | 2025-12-31 | -$276.39M | n/m |
| Fortress Biotech, Inc. (FBIO) | 2025-12-31 | -$65.78M | n/m |
| Assembly Biosciences, Inc. (ASMB) | 2025-12-31 | -$41.09M | n/m |
| Nuvation Bio Inc. (NUVB) | 2025-12-31 | -$173.43M | n/m |
| Bicycle Therapeutics PLC (BCYC) | 2025-12-31 | -$249.68M | n/m |
Compare KURA, SPRO, RMTI, ENTA side by side · Screen every company in Pharmaceutical Preparations ↗